312488-55-4

Upstream product

• 77-78-1 dimethyl sulfate 
• 142-61-0 Hexanoyl chloride 
• 151-10-0 1,3-Dimethoxybenzene 

Downstream Products

• 312488-56-5 ethyl (Z)-3-(2,4-dimethoxyphenyl)-2-octenate 
• 312488-57-6 ethyl (E)-3-(2,4-dimethoxyphenyl)-2-octenate 
• 117690-68-3 5-(4-Acetyl-2-hexyl-5-hydroxyphenoxy)-pentanenitrile 
• 117690-83-2 5-Hexyl-2,4-dimethoxyacetophenone 
• 17715-58-1 3-hexyl-2,6-dimethoxybenzene 
• 63411-88-1 1-(5-hexyl-2,4-dihydroxyphenyl) ethan-1-one 
• 254907-06-7 (Z)-3-(2,4-dimethoxyphenyl)oct-2-enoic acid 

Relevant academic research and scientific papers

Ketide compounds, method for manufacturing, and use for treating diabetes thereof

The present invention relates to ketide compounds, as well as ketide compounds. The present invention relates to a method for preparing a ketide compound, and a use thereof, in which various anti-diabetic TMPA derivative designs can be induced, and is effective in comparison with existing multi-stage synthesis. In addition, the ketide compounds according to the present invention have strong AMPMPK activity and are expected to be useful as a therapeutic agent for diabetes. (by machine translation)

Enantioselective synthesis of the key intermediate of the acyl-CoA: Cholesterol acyltransferase (ACAT) inhibitor (R-106578) using 2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl (BINAP)-Ru(OAc)2 as a catalyst

Acidic segment of an acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor, R-106578 was synthesized by enantioselective hydrogenation of the Z-olefine (9-(Z)) using (R)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP)-Ru(OAc)2 as a catalys

Leukotriene B4 Receptor Antagonists: The LY255283 Series of Hydroxyacetophenones

A series of hydroxyacetophenones was prepared for evaluation as leukotriene B4 (LTB4) receptor antagonists, culminating in 1-oxy>phenyl>ethanone (compound 35, LY255283).Using an assay for inhibition of specific LTB4 binding to human PMN, we found that substitution of a nonpolar substituent in the 5-position was required for activity.Best activity was realized with hydrogen in the 3-position, hydroxyl in the 2-position, short chain alkyl ketone in the 1-position, and a six- or eight-carbon chain linking the oxygen in the 4-position with an unsaturated terminal function.Compound 35, having an IC50 of 87 nM in the binding assay, was chosen for further preclinical evaluation.